Product logins

Find logins to all Clarivate products below.


Upper Tract Urothelial Carcinoma – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key upper tract urothelial carcinoma patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to do the following:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact healthcare.support@clarivate.com.

Related Market Assessment Reports

Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
Report
Ulcerative Colitis – Epidemiology – Epidemiology – Ulcerative Colitis – Mature Markets
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Report
Emerging Vaccines – Epidemiology – Epidemiology – Emerging Vaccines- Mature Markets
Clarivate Epidemiology’s coverage of emerging vaccines comprises epidemiological estimates of eligible populations in the major mature pharmaceutical markets (United States, France, Germany,…